Treatment cost analysis highlights systemic health inequities faced by persons with sickle cell disease
A new distributional cost-effectiveness analysis of gene therapy versus standard-of-care for sickle cell disease (SCD) found that while gene therapy is cost-ineffective by conventional measures, it can be an equitable therapeutic strategy for persons living with SCD in the United States when equity, cost, and value of treatment are considered together.
These findings highlight systemic health inequities faced by persons with sickle cell disease (SCD). The authors say this is the first quantitative consideration of health equity for patients with SCD regarding the decision between gene therapy and standard care and the first study of its kind in any rare disease. The analysis is published in Annals of Internal Medicine.
Researchers from Yale University School of Medicine studied claims data and other published sources to compare gene therapy versus standard-of-care in patients with SCD by using conventional cost-effectiveness and distributional cost-effectiveness measures. While conventional cost-effectiveness analysis does not capture the effects of treatments on disparities, distributional cost-effectiveness uses equity weights to incorporate these considerations. The authors found that the total quality-adjusted life years, or QALYs, for persons receiving gene therapy treatment for SCD would cost $2.8 million versus $1.2 million for persons receiving standard care. According to the authors, the inequality aversion parameter would need to be 0.90 for the full SCD population for gene therapy to be preferred per distributional cost-effectiveness standards. This is right in line with benchmark values previously reported in the United States for inequality aversion (range: 0.5-3.0), with higher values representing a higher emphasis on reducing a particular health disparity.